Switch theme
Sign up to access all valuation multiples
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
2020
5.1K+
LTM Revenue $1.1B
LTM EBITDA $169M
$3.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Piramal Pharma has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $169M.
In the most recent fiscal year, Piramal Pharma achieved revenue of $1.1B and an EBITDA of $194M.
Piramal Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Piramal Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $700M | XXX | $693M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 65% | XXX | XXX | XXX |
| EBITDA | $169M | XXX | $194M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| EBIT | $77.6M | XXX | $73.6M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $12.3M | XXX | $10.7M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 1% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $510M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Piramal Pharma's stock price is INR 206 (or $2).
Piramal Pharma has current market cap of INR 273B (or $3.2B), and EV of INR 316B (or $3.7B).
See Piramal Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.7B | $3.2B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Piramal Pharma has market cap of $3.2B and EV of $3.7B.
Piramal Pharma's trades at 3.6x EV/Revenue multiple, and 20.0x EV/EBITDA.
Equity research analysts estimate Piramal Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Piramal Pharma has a P/E ratio of 260.7x.
See valuation multiples for Piramal Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.2B | XXX | $3.2B | XXX | XXX | XXX |
| EV (current) | $3.7B | XXX | $3.7B | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | 20.0x | XXX | XXX | XXX |
| EV/EBIT | 47.7x | XXX | 54.6x | XXX | XXX | XXX |
| EV/Gross Profit | 5.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 260.7x | XXX | 375.4x | XXX | XXX | XXX |
| EV/FCF | 297.2x | XXX | 129.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPiramal Pharma's last 12 month revenue growth is 9%
Piramal Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Piramal Pharma's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Piramal Pharma's rule of X is 37% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Piramal Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 9% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 26% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Piramal Pharma acquired XXX companies to date.
Last acquisition by Piramal Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Piramal Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Piramal Pharma founded? | Piramal Pharma was founded in 2020. |
| Where is Piramal Pharma headquartered? | Piramal Pharma is headquartered in India. |
| How many employees does Piramal Pharma have? | As of today, Piramal Pharma has 5.1K+ employees. |
| Who is the CEO of Piramal Pharma? | Piramal Pharma's CEO is Mr. Peter DeYoung. |
| Is Piramal Pharma publicy listed? | Yes, Piramal Pharma is a public company listed on BOM. |
| What is the stock symbol of Piramal Pharma? | Piramal Pharma trades under 543635 ticker. |
| When did Piramal Pharma go public? | Piramal Pharma went public in 2022. |
| Who are competitors of Piramal Pharma? | Similar companies to Piramal Pharma include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Piramal Pharma? | Piramal Pharma's current market cap is $3.2B |
| What is the current revenue of Piramal Pharma? | Piramal Pharma's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Piramal Pharma? | Piramal Pharma revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Piramal Pharma? | Current revenue multiple of Piramal Pharma is 3.4x. |
| Is Piramal Pharma profitable? | Yes, Piramal Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Piramal Pharma? | Piramal Pharma's last 12 months EBITDA is $169M. |
| What is Piramal Pharma's EBITDA margin? | Piramal Pharma's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Piramal Pharma? | Current EBITDA multiple of Piramal Pharma is 21.8x. |
| What is the current FCF of Piramal Pharma? | Piramal Pharma's last 12 months FCF is $12.5M. |
| What is Piramal Pharma's FCF margin? | Piramal Pharma's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Piramal Pharma? | Current FCF multiple of Piramal Pharma is 297.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
